109 related articles for article (PubMed ID: 25658615)
1. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.
Imahashi N; Nishida T; Goto T; Terakura S; Watanabe K; Hanajiri R; Sakemura R; Imai M; Kiyoi H; Naoe T; Murata M
J Immunother; 2015; 38(2):62-70. PubMed ID: 25658615
[TBL] [Abstract][Full Text] [Related]
2. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
4. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
5. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
7. Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells.
Zhang GB; Dong QM; Hou JQ; Ge Y; Ju SG; Lu BF; Zhang XG
Tissue Antigens; 2007 Dec; 70(6):470-9. PubMed ID: 17990986
[TBL] [Abstract][Full Text] [Related]
8. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
9. Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation.
Chono H; Goto Y; Yamakawa S; Tanaka S; Tosaka Y; Nukaya I; Mineno J
J Biochem; 2011 Mar; 149(3):285-92. PubMed ID: 21106541
[TBL] [Abstract][Full Text] [Related]
10. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
DeBenedette MA; Shahinian A; Mak TW; Watts TH
J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy.
Choi BK; Lee SC; Lee MJ; Kim YH; Kim YW; Ryu KW; Lee JH; Shin SM; Lee SH; Suzuki S; Oh HS; Kim CH; Lee DG; Hwang SH; Yu EM; Lee IO; Kwon BS
J Immunother; 2014 May; 37(4):225-36. PubMed ID: 24714356
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of agonistic 4-1BB (CD137) monoclonal antibody on the maturation and functions of hypoxic dendritic cells.
Shang Q; Dong Z; Liu C; Bai Y; Guo C; Zhang L; Wang Q
Int Immunopharmacol; 2014 Dec; 23(2):609-16. PubMed ID: 25466269
[TBL] [Abstract][Full Text] [Related]
13. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
14. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of anti-human 4-1BB monoclonal antibody and characterization of its biological activities].
Zhou H; Zhang GB; Dong QM; Yu GH; Xu Y; Zhang XG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):993-6. PubMed ID: 21906475
[TBL] [Abstract][Full Text] [Related]
16. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
17. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
18. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
Hurtado JC; Kim YJ; Kwon BS
J Immunol; 1997 Mar; 158(6):2600-9. PubMed ID: 9058792
[TBL] [Abstract][Full Text] [Related]
19. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
20. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]